Carlotta Antoniotti

Pisa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications

Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration.

Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration.

Journal: Cancer treatment reviews
Published: January 31, 2026

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2026

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 05, 2025

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 04, 2025

Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO.

Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 20, 2025

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

Journal: JCO precision oncology
Published: April 18, 2025

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2025

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 30, 2025

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study.

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study.

Journal: ESMO open
Published: December 02, 2024

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm.

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm.

Journal: Nature reviews. Clinical oncology
Published: October 25, 2024

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Journal: JCO clinical cancer informatics
Published: July 17, 2024

Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy.

Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy.

Journal: Therapeutic advances in medical oncology
Published: July 02, 2024
Showing 1-12 of 108

Last Updated: 09/26/2026